About Corcept
Corcept is a company based in Menlo Park (United States) founded in 1998. The company has 500 employees as of December 31, 2024. Corcept offers products and services including Cortisol Modulation Pipeline. Corcept operates in a competitive market with competitors including NGM Biopharmaceuticals, MannKind Corp, Rhythm Pharmaceuticals, ViaCyte and 89bio, among others.
- Headquarter Menlo Park, United States
- Employees 500 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Corcept Therapeutics Incorporated
-
Annual Revenue
$675.04 M (USD)39.94as on Dec 31, 2024
-
Net Profit
$139.73 M (USD)32.45as on Dec 31, 2024
-
EBITDA
$138.29 M (USD)27.66as on Dec 31, 2024
-
Latest Funding Round
Not available
-
Investors
Investor Growth Capital
& 4 more
-
Employee Count
500
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Corcept
Corcept is a publicly listed company on the NASDAQ with ticker symbol CORT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Corcept
Corcept offers a comprehensive portfolio of products and services, including Cortisol Modulation Pipeline.
Develops treatments for diseases affected by cortisol through clinical trials.
People of Corcept
Unlock access to complete
Unlock access to complete
Sales and Marketing
41 people
Leadership Team
36 people
Software Development Team
13 people
Finance and Accounting
13 people
Product Management Team
12 people
Senior Team
8 people
Operations Team
8 people
Data Analysis and Operations Team
7 people
Unlock access to complete
Funding Insights of Corcept
Investors in Corcept
Corcept has secured backing from 5 investors, including venture fund investors. Prominent investors backing the company include Investor Growth Capital, Longitude Capital and Sutter Hill Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Corporate-backed venture capital firm focused on fintech, energy, and multiple sectors
|
Locked | Locked | Locked | |
|
Private equity firm focused on life science sector
|
Locked | Locked | Locked | |
|
VC firm investing in the US
|
Locked | Locked | Locked |
Investor details for Corcept
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Corcept
Investment portfolio details for Corcept
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Corcept
Detailed financials for Corcept
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Corcept Comparisons
Peer comparison for Corcept
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Corcept
Corcept operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NGM Biopharmaceuticals, MannKind Corp, Rhythm Pharmaceuticals, ViaCyte and 89bio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Biologics are developed for cardio-metabolic and liver diseases.
|
|
| Locked | Locked | Locked |
Developer of small-molecule drugs
|
|
| Locked | Locked | Locked |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
|
| Locked | Locked | Locked |
Cell therapy for diabetes is developed from stem cells.
|
|
| Locked | Locked | Locked |
Developer of therapies for treating nonalcoholic steatohepatitis and other liver and metabolic disorders
|
Detailed competitors of Corcept
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Corcept
Complete news archive for Corcept
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Corcept
Corcept was founded in 1998 and raised its 1st funding round 8 years after it was founded.
Corcept is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
As of Dec 31, 2024, the latest employee count at Corcept is 500.
Annual revenue of Corcept is $675.04M as on Dec 31, 2024.
Developer of cortisol modulators for the treatment of various diseases. The company focuses on the discovery and development of drugs that modulate the effects of cortisol that target glucocorticoid receptor (GR) antagonists to treat a variety of endocrine, metabolic, oncologic, psychiatric, and ophthalmologic diseases.
Corcept's top competitors include Rhythm Pharmaceuticals, MannKind Corp and NGM Biopharmaceuticals.
Corcept offers Cortisol Modulation Pipeline.
Yes, Corcept is publicly traded on NASDAQ under the ticker symbol CORT.
Corcept has 5 investors. Key investors include Investor Growth Capital, Longitude Capital, Sutter Hill Ventures, Alta Partners, and Paperboy Ventures.
The ticker symbol of Corcept is CORT on NASDAQ.